» Articles » PMID: 39281195

The Brain Network Hub Degeneration in Alzheimer's Disease

Overview
Journal Biophys Rep
Specialty Biochemistry
Date 2024 Sep 16
PMID 39281195
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) has been conceptualized as a syndrome of brain network dysfunction. Recent imaging connectomics studies have provided unprecedented opportunities to map structural and functional brain networks in AD. By reviewing molecular, imaging, and computational modeling studies, we have shown that highly connected brain hubs are primarily distributed in the medial and lateral prefrontal, parietal, and temporal regions in healthy individuals and that the hubs are selectively and severely affected in AD as manifested by increased amyloid-beta deposition and regional atrophy, hypo-metabolism, and connectivity dysfunction. Furthermore, AD-related hub degeneration depends on the imaging modality with the most notable degeneration in the medial temporal hubs for morphological covariance networks, the prefrontal hubs for structural white matter networks, and in the medial parietal hubs for functional networks. Finally, the AD-related hub degeneration shows metabolic, molecular, and genetic correlates. Collectively, we conclude that the brain-network-hub-degeneration framework is promising to elucidate the biological mechanisms of network dysfunction in AD, which provides valuable information on potential diagnostic biomarkers and promising therapeutic targets for the disease.

References
1.
van den Heuvel M, Kahn R, Goni J, Sporns O . High-cost, high-capacity backbone for global brain communication. Proc Natl Acad Sci U S A. 2012; 109(28):11372-7. PMC: 3396547. DOI: 10.1073/pnas.1203593109. View

2.
Cho H, Choi J, Hwang M, Kim Y, Lee H, Lee H . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016; 80(2):247-58. DOI: 10.1002/ana.24711. View

3.
Wang X, Zeng Y, Chen G, Zhang Y, Li X, Hao X . Abnormal organization of white matter networks in patients with subjective cognitive decline and mild cognitive impairment. Oncotarget. 2016; 7(31):48953-48962. PMC: 5226483. DOI: 10.18632/oncotarget.10601. View

4.
Menardi A, Dotti L, Ambrosini E, Vallesi A . Transcranial magnetic stimulation treatment in Alzheimer's disease: a meta-analysis of its efficacy as a function of protocol characteristics and degree of personalization. J Neurol. 2022; 269(10):5283-5301. PMC: 9468063. DOI: 10.1007/s00415-022-11236-2. View

5.
Lim H, Nebes R, Snitz B, Cohen A, Mathis C, Price J . Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain. 2014; 137(Pt 12):3327-38. PMC: 4240287. DOI: 10.1093/brain/awu271. View